ALFA Finder| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 2370.0 | 2229.4 | 1966.4 |
| Other income | 14.4 | 19.9 | 9.8 |
| Total income | 2384.4 | 2249.3 | 1976.2 |
| Profit before exceptional items & tax | 61.7 | 86.4 | 196.1 |
| Exceptional items | 0.0 | 0.0 | -5.8 |
| Profit before tax | 61.7 | 86.4 | 190.3 |
| Net profit | 31.0 | 56.4 | 119.9 |
| Operating margin | 2.6% | 3.8% | 9.6% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -74.10% |
|---|---|
| Net profit, quarter on quarter | -45.00% |
| Revenue, year on year | +20.50% |
| Operating profit, year on year | -74.60% |
| Operating profit, quarter on quarter | -28.90% |
NSE results filing, NSE: JUBLPHARMA. Figures extracted from the filing.
Jubilant Pharmova Ltd: key numbers
- Share price
- ₹964.65
- Market cap
- ₹15,365 Cr
- Revenue (annual)
- ₹8,280 Cr
- Net profit (annual)
- ₹398.5 Cr
- P/E (TTM)
- 43.6×Sector 43.8×
- Promoter holding
- 47.68%+0.00% QoQ
- FII holding
- 15.37%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Jubilant Pharmova Ltd
All →Jubilant Pharmova Results Update
Q2 revenue rose 21% to Rs 2,370 Cr, but EBITDA fell 27% and PAT dropped to Rs 31 Cr. SPECT supply gaps and remediation costs compressed margins.
Jubilant Pharmova Business Update
Jubilant Pharmova's subsidiary Jubilant Therapeutics will present preliminary Phase 1 clinical data for JBI-802 at the 68th ASH meeting. A company event on December 14, 2026 will discuss the data.
Jubilant Pharmova Debt & Borrowing: ₹800 Cr
Jubilant Pharmova allotted 80,000 unsecured NCDs worth Rs 800 Crore on a private placement basis. The 8.50% debentures mature in November 2028.
- Value
- ₹800.0 Cr
- Execution
- 3 years (maturity 05 November 2028)
Jubilant Pharmova Board Meeting Date
Jubilant Pharmova has scheduled a board meeting for November 13, 2026 to consider unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026. The filing is a Regulation 29 advance intimation only.
Jubilant Pharmova Annual General Meeting
Jubilant Pharmova Ltd has issued a Postal Ballot Notice seeking shareholder approval for the private placement issuance of Non-Convertible Debentures.
Jubilant Pharmova Credit Rating
Jubilant Pharmova received a credit rating of IND AA+/Stable from India Ratings and Research for its proposed Non-Convertible Debentures worth ₹1,400 Crore.
- Value
- ₹1,400 Cr